Upgrade to SI Premium - Free Trial

UPDATE: Valeant Pharmaceuticals (VRX) PT Lowered to $19 at BMO Capital Following 4Q Results; 'Entering Transitional Period'

March 1, 2017 6:09 AM
(Updated - March 1, 2017 6:19 AM EST)

BMO Capital analyst Gary Nachman lowered its price target on Valeant ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles